BKA
SRPT icon

Brick & Kyle Associates’s Sarepta Therapeutics SRPT Stock Holding History

Brick & Kyle Associates’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-300
Closed -$6K – 440
2016
Q1 		$6K Hold
300
– – 0.01% 379
2015
Q4 		$12K Buy
+300
New +$9.73K 0.01% 321

Other funds holding SRPT

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Brick & Kyle Associates's SRPT Position: Q2 2016 in Review

Brick & Kyle Associates sold out of Sarepta Therapeutics (SRPT) in Q2 2016, closing a stake of 300 shares — an estimated $6K sold.

Brick & Kyle Associates first reported a position in SRPT in Q4 2015 and held it in 2 quarters. The position peaked at $12K in Q4 2015. 148 funds tracked by Wall St. Rank hold SRPT as of Q2 2016.

  • Brick & Kyle Associates reported no remaining Sarepta Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Brick & Kyle Associates sold 300 Sarepta Therapeutics shares in Q2 2016, an estimated $6K.
  • Brick & Kyle Associates first reported a position in Sarepta Therapeutics in Q4 2015 and held it in 2 quarters.
  • Brick & Kyle Associates's Sarepta Therapeutics position peaked at $12K in Q4 2015.
  • 148 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2016.

Based on Brick & Kyle Associates's 13F filing for Q2 2016, filed 5 Aug 2016.